Form 4: BioAdaptives Director Receives Equity Compensation

BioAdaptives, Inc. director Mark P. Frissora received 1,517 shares of Series D Convertible Preferred Stock as compensation for board services.

Summary

• Director Mark P. Frissora acquired 1,517 shares of Series D Convertible Preferred Stock on October 1, 2025, as compensation for board services.
• The compensation was issued pursuant to a Board of Directors Agreement dated February 3, 2025.
• Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, implying 151,700 common shares for this transaction.
• Conversion is subject to a 10% beneficial ownership limitation and cannot occur until six months after the issuance date, except in the case of liquidation.
• The Series D Convertible Preferred Stock carries 100 votes per share on matters of the Issuer, without regard to the beneficial ownership limitation.
• Following this transaction, Mark P. Frissora beneficially owns a total of 51,524 shares of Series D Convertible Preferred Stock, which could convert into 5,152,400 shares of common stock.

Sentiment

Score: 6

Explanation: The filing reports routine director compensation through equity, which is generally positive for aligning interests. However, the specific terms of the convertible preferred stock, including significant voting power and potential future dilution, introduce elements that warrant careful consideration, leading to a slightly positive but cautious sentiment.

Positives

• Aligns the interests of Director Mark P. Frissora with those of shareholders through equity-based compensation.
• Provides a non-cash compensation method for board services, preserving cash for company operations.

Negatives

• Potential for future dilution of common stock value if the Series D Convertible Preferred Stock is converted into common shares.
• The Series D Convertible Preferred Stock carries significant voting power (100 votes per share), potentially concentrating voting influence.

Risks

• Potential future dilution of common stock shareholders upon conversion of Series D Convertible Preferred Stock, although subject to a 10% beneficial ownership limitation.
• Complexity of Series D Convertible Preferred Stock terms, including conversion restrictions (six-month lock-up) and significant voting rights (100 votes per share), which could impact common shareholder influence.

Future Outlook

The Series D Convertible Preferred Stock cannot be converted into common stock until six months after the issuance date (April 1, 2026), except in the event of liquidation. The right to convert does not expire.

Industry Context

Equity compensation for directors is a common practice across industries, aiming to align the interests of board members with those of shareholders. The use of convertible preferred stock can offer flexibility in compensation structure while managing immediate dilution.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice, often involving stock options, restricted stock units, or, as in this case, convertible preferred stock.
• The 100:1 conversion ratio and 100 votes per preferred share are specific to this company's capital structure and may differ significantly from other companies' preferred stock terms, which vary widely based on negotiation and company needs.
• A six-month lock-up period before conversion is a common mechanism to manage immediate market impact and ensure long-term alignment.

Corporate Governance

Related Party Transactions

• Issuance of 1,517 shares of Series D Convertible Preferred Stock to Director Mark P. Frissora as compensation for board services, pursuant to a Board of Directors Agreement dated February 3, 2025.

Stakeholder Impact

• Shareholders: Potential for future dilution of common stock upon conversion of preferred shares, but also improved alignment of director interests.
• Director (Mark P. Frissora): Receives equity compensation for services, increasing his stake and aligning his financial interests with the company's performance.

Next Steps

• The Series D Convertible Preferred Stock held by Mark P. Frissora will become convertible into common stock on April 1, 2026, subject to a 10% beneficial ownership limitation.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving director compensation through convertible preferred stock. While it aligns director interests with shareholders, it does not present new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The potential for future dilution is noted but is a common aspect of equity compensation plans.

Keywords

BIOADAPTIVES, BDPT, Form 4, Insider Transaction, Director Compensation, Convertible Preferred Stock, Equity Compensation, Mark P. Frissora